Non-coding recurrent mutations in chronic lymphocytic leukaemia

Nature

Volumn 526, Issue 7574, 2015, Pages 519-524

  Puente, Xose S ^a   Beà, Silvia ^b   Valdés Mas, Rafael ^a   Villamor, Neus ^c   Gutiérrez Abril, Jesús ^a   Martín Subero, José I ^c   Munar, Marta ^c   Rubio Pérez, Carlota ^d   Jares, Pedro ^b   Aymerich, Marta ^c   Baumann, Tycho ^e   Beekman, Renée ^b   Belver, Laura ^f   Carrio, Anna ^c   Castellano, Giancarlo ^b   Clot, Guillem ^b   Colado, Enrique ^g   Colomer, Dolors ^c   Costa, Dolors ^c   Delgado, Julio ^e   Enjuanes, Anna ^b   Estivill, Xavier ^d   Ferrando, Adolfo A ^f   Gelpí, Josep L ^c   González, Blanca ^c   González, Santiago ^c   González, Marcos ^h   Gut, Marta ^c   Hernández Rivas, Jesús M ^h   López Guerra, Mónica ^c   Martín García, David ^b   Navarro, Alba ^b   Nicolás, Pilar ⁱ   Orozco, Modesto ^c   Payer, Ángel R ^g   Pinyol, Magda ^b   Pisano, David G ^j   Puente, Diana A ^a   Queirós, Ana C ^c   Quesada, Víctor ^a   Romeo Casabona, Carlos M ⁱ   Royo, Cristina ^b   Royo, Romina ^c   Rozman, María ^c   Russiñol, Nuria ^b   Salaverría, Itziar ^b   Stamatopoulos, Kostas ^k   Stunnenberg, Hendrik G ^l   Tamborero, David ^d   Terol, María J ^m   Valencia, Alfonso ^j   López Bigas, Nuria ^d   Torrents, David ^c   Gut, Ivo ^c   López Guillermo, Armando ^e   López Otín, Carlos ^a   Campo, Elías ^c   more..

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f Howard Hughes Medical Institute   (United States)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ UNIVERSITY OF DEUSTO   (Spain)

^j Centro Nacional de Investigations Oncológicas   (Spain)

^k INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARID1A PROTEIN; NOTCH1 RECEPTOR; PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; ZMYM3 PROTEIN; ZNF292 PROTEIN; 3' UNTRANSLATED REGION; ARID1A PROTEIN, HUMAN; CARRIER PROTEIN; DNA; NERVE PROTEIN; NOTCH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PAX5 PROTEIN, HUMAN; PTPN11 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; ZMYM3 PROTEIN, HUMAN; ZNF292 PROTEIN, HUMAN;

ANTIBODY; BLOOD; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; GENETIC VARIATION; MUTATION;

3' UNTRANSLATED REGION; ARTICLE; CHROMOSOME 9P; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ACTIVITY; ENHANCER REGION; GENE MUTATION; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MONOCLONAL B CELL LYMPHOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; SPLICING DEFECT; ALTERNATIVE RNA SPLICING; B LYMPHOCYTE; BIOSYNTHESIS; CHROMOSOME 9; GENETICS; GENOMICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

3' UNTRANSLATED REGIONS; ALTERNATIVE SPLICING; B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 9; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENHANCER ELEMENTS, GENETIC; GENOMICS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RECEPTOR, NOTCH1; TRANSCRIPTION FACTORS;

EID: 84945248976     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14666     Document Type: Article

References (57)

1. Gaidano, G., Foa, R. & Dalla-Favera, R. Molecular pathogenesis of chronic lymphocytic leukemia. J. Clin. Invest. 122, 3432-3438 (2012).
2. Zenz, T.,Mertens, D., Kuppers, R., Dohner,H.& Stilgenbauer, S. Frompathogenesis to treatment of chronic lymphocytic leukaemia. Nature Rev. Cancer 10, 37-50 (2010).
3. Pekarsky, Y., Zanesi, N. & Croce, C. M. Molecular basis of CLL. Semin. Cancer Biol. 20, 370-376 (2010).
4. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. & Stevenson, F. K. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848-1854 (1999).
5. Damle, R. N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840-1847 (1999).
6. Crespo, M. et al. ZAP-70 expression as a surrogate for immunoglobulin-variableregion mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348, 1764-1775 (2003).
7. Malek, S. N. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene 32, 2805-2817 (2013).
8. Döhner, H. et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910-1916 (2000).
9. Quesada, V. et al. Exome sequencing identifies recurrentmutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genet. 44, 47-52 (2011).
10. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
11. Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013).
12. Fabbri, G. et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208, 1389-1401 (2011).
13. Ramsay, A. J. et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nature Genet. 45, 526-530 (2013).
14. Damm, F. et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 4, 1088-1101 (2014).
15. Rossi, D. et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119, 2854-2862 (2012).
16. Ferreira, P. G. et al. Transcriptomecharacterization byRNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res. 24, 212-226 (2014).
17. Kulis, M. et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nature Genet. 44, 1236-1242 (2012).
18. Oakes, C. C. et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 4, 348-361 (2014).
19. Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993-998 (2010).
20. Alexandrov, L. B. et al. Signatures ofmutational processes in humancancer. Nature 500, 415-421 (2013).
21. Khodabakhshi, A. H. et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget 3, 1308-1319 (2012).
22. Pasqualucci, L. et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412, 341-346 (2001).
23. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32-42 (2013).
24. Moncunill, V. et al. Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. Nature Biotechnol. 32, 1106-1112 (2014).
25. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011).
26. Baca, S. C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666-677 (2013).
27. Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59-71 (2012).
28. Balatti, V. et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 119, 329-331 (2012).
29. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959 (2013).
30. Yamane, A. et al. Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nature Immunol. 12, 62-69 (2011).
31. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
32. Simonis, M.,Kooren, J.&de Laat,W.An evaluation of 3C-basedmethods to capture DNA interactions. Nature Methods 4, 895-901 (2007).
33. Revilla-i-Domingo, R. et al. The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. EMBO J. 31, 3130-3146 (2012).
34. Queiró s, A. C. et al. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia 29, 598-605 (2015).
35. Strefford, J. C. et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 27, 2196-2199 (2013).
36. Agathangelidis, A. et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 119, 4467-4475 (2012).
37. Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382-396 (2015).
38. Lobry, C., Oh, P. & Aifantis, I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J. Exp. Med. 208, 1931-1935 (2011).
39. O'Brien, P., Morin, P. Jr, Ouellette, R. J. & Robichaud, G. A. The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. Cancer Res. 71, 7345-7350 (2011).
40. Villamor, N. et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patientswith high risk of transformation and poor outcome. Leukemia 27, 1100-1106 (2013).
41. Bentley, D. R. et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456, 53-59 (2008).
42. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
43. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
44. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
45. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246-259 (2013).
46. Delgado, J. et al. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica 99, e231-e234 (2014).
47. Edelmann, J. et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120, 4783-4794 (2012).
48. Valdés-Mas, R., Bea, S., Puente, D. A., Lopez-Otin, C. & Puente, X. S. Estimation of copy number alterations from exome sequencing data. PLoS ONE 7, e51422 (2012).
49. Bibikova, M. et al. High density DNA methylation array with single CpG site resolution. Genomics 98, 288-295 (2011).
50. Bibikova, M. et al. Genome-wide DNA methylation profiling using InfiniumR assay. Epigenomics 1, 177-200 (2009).
51. Aryee,M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of InfiniumDNAmethylationmicroarrays. Bioinformatics 30, 1363-1369 (2014).
52. Kluk, M. J. et al. Gauging NOTCH1 activation in cancer using immunohistochemistry. PLoS ONE 8, e67306 (2013).
53. van deWerken, H. J. et al.Robust4C-seq data analysis to screen for regulatoryDNA interactions. Nature Methods 9, 969-972 (2012).
54. van de Werken, H. J. et al. 4C technology: protocols and data analysis. Methods Enzymol. 513, 89-112 (2012).
55. Heckl, D. et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nature Biotechnol. 32, 941-946 (2014).
56. Heigwer, F., Kerr, G. & Boutros, M. E-CRISP: fast CRISPR target site identification. Nature Methods 11, 122-123 (2014).
57. Peto, R. & Pike, M. C. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics 29, 579-584 (1973).